Innovation, investment, and ideals intersected dramatically at the AI Action Summit—held 10–11 February at Paris’s Grand Palais. Co-chaired …
Innovation, investment, and ideals intersected dramatically at the AI Action Summit—held 10–11 February at Paris’s Grand Palais. Co-chaired …
The FDA has approved SPN-830 (Onapgo)—a novel subcutaneous apomorphine infusion device—offering continuous, effective management of motor fluctuations in …
Sarepta Therapeutics reports encouraging Phase III trial data for Elevidys, its AAV-based gene therapy for Duchenne muscular dystrophy, …
Daiichi Sankyo’s antibody–drug conjugate Datopotamab Deruxtecan secures U.S. approval, offering a new treatment for patients with previously treated …
Stablepharma moves toward first-in-human testing of SPVX02, a thermally stable tetanus–diphtheria booster that could revolutionise vaccine storage and …
A novel collaboration breaks ground with an inhaled mRNA therapy entering early clinical testing for the first time—a …
Generative AI has produced a novel TNIK-inhibiting compound now advancing in phase 2a trials—an unprecedented milestone in drug discovery.
The NHS is set to trial an AI-based solution that can forecast type 2 diabetes risk by analyzing …
Late-December 2024 sees the launch of Australia’s first government-backed clinical trial using AI-guided neuromodulation to tackle severe, treatment-resistant …
Caption By the end of 2024, emerging studies point to GLP‑1 receptor agonists—once mainly weight‑loss drugs—finding versatile application …
Already a subscriber? Log in